These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 14975680

  • 1. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV, Cooper JM, Schapira AH.
    Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
    [Abstract] [Full Text] [Related]

  • 2. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC, Lambert JD.
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [Abstract] [Full Text] [Related]

  • 3. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.
    Haasio K, Nissinen E, Sopanen L, Heinonen EH.
    J Neural Transm (Vienna); 2002 Nov; 109(11):1391-401. PubMed ID: 12454735
    [Abstract] [Full Text] [Related]

  • 4. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells.
    Grünig D, Felser A, Bouitbir J, Krähenbühl S.
    Toxicol In Vitro; 2017 Aug; 42():337-347. PubMed ID: 28526448
    [Abstract] [Full Text] [Related]

  • 5. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ, Michaelis S, Schrey AK, Graebner OG, Glinski M, Dreger M, Kroll F, Koester H.
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [Abstract] [Full Text] [Related]

  • 6. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM, Rinne UK.
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [Abstract] [Full Text] [Related]

  • 7. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K, Sopanen L, Vaalavirta L, Lindén IB, Heinonen EH.
    J Neural Transm (Vienna); 2001 Nov; 108(1):79-91. PubMed ID: 11261749
    [Abstract] [Full Text] [Related]

  • 8. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
    Haasio K, Lounatmaa K, Sukura A.
    Exp Toxicol Pathol; 2002 Jul; 54(1):9-14. PubMed ID: 12180806
    [Abstract] [Full Text] [Related]

  • 9. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M, Ukai W, Ozawa H, Riederer P.
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [Abstract] [Full Text] [Related]

  • 10. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S.
    Int Rev Neurobiol; 2010 May; 95():207-25. PubMed ID: 21095464
    [Abstract] [Full Text] [Related]

  • 11. Practical issues with COMT inhibitors in Parkinson's disease.
    Waters C.
    Neurology; 2000 May; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
    [Abstract] [Full Text] [Related]

  • 12. New options for treatment of Parkinson's disease.
    LeWitt PA.
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [Abstract] [Full Text] [Related]

  • 13. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 14. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
    Kieburtz K, Hubble J.
    Neurology; 2000 Jan; 55(11 Suppl 4):S42-5; discussion S46-50. PubMed ID: 11147509
    [Abstract] [Full Text] [Related]

  • 15. Effects of entacapone and tolcapone on mitochondrial membrane potential.
    Haasio K, Koponen A, Penttilä KE, Nissinen E.
    Eur J Pharmacol; 2002 Oct 18; 453(1):21-6. PubMed ID: 12393055
    [Abstract] [Full Text] [Related]

  • 16. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
    De Santi C, Giulianotti PC, Pietrabissa A, Mosca F, Pacifici GM.
    Eur J Clin Pharmacol; 1998 May 18; 54(3):215-9. PubMed ID: 9681662
    [Abstract] [Full Text] [Related]

  • 17. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
    Forsberg MM, Huotari M, Savolainen J, Männistö PT.
    Eur J Pharm Sci; 2005 Apr 18; 24(5):503-11. PubMed ID: 15784340
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Järvinen T, Männistö PT.
    J Pharmacol Exp Ther; 2003 Feb 18; 304(2):498-506. PubMed ID: 12538800
    [Abstract] [Full Text] [Related]

  • 19. COMT inhibitors and liver toxicity.
    Watkins P.
    Neurology; 2000 Feb 18; 55(11 Suppl 4):S51-2; discussion S53-6. PubMed ID: 11147510
    [Abstract] [Full Text] [Related]

  • 20. Issues important for rational COMT inhibition.
    Dingemanse J.
    Neurology; 2000 Feb 18; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.